BioIntelliSense, Inc., a continuous health monitoring and clinical intelligence company, has launched its medical grade Data-as-a-Service (DaaS) platform and FDA 510(k) clearance of the BioSticker on-body sensor for scalable remote care. The sensor is designed to provide a new standard for Remote Patient Monitoring (RPM) by combining an effortless patient experience with medical grade clinical accuracy and cost-effective data services.
The BioSticker is an advanced on-body sensor that allows for effortless continuous monitoring of vital signs and actionable insights, delivered to clinicians from patients in the home setting, thereby creating opportunities for early detection of potentially avoidable complications. BioIntelliSense claims that through the platform's data sets and analytics, highly-efficient care is now possible at a fraction of the cost of traditional remote patient monitoring.
"We are at the inception of a remarkable new era in healthcare that will employ medical grade sensor technologies to effortlessly capture remote patient data and generate personalized clinical intelligence," said James Mault, MD, FACS, CEO of BioIntelliSense, in a statement.
BioIntelliSense is built on the foundation of a team of engineers and data scientists with decades of expertise in wearable sensor development. The company has established a strategic collaboration with UCHealth and its CARE Innovation Center to demonstrate the value and clinical applications of the BioSticker device and medical-grade services. This alliance is committed to develop and validate new models of data-driven care that are patient-centered and built for scale.
"The future of healthcare will see the lines blurred between the hospital, clinic and home," said Dr. Richard Zane, UCHealth Chief Innovation Officer and Chair of Emergency Medicine at the University of Colorado School of Medicine, in a statement. "The use of the BioSticker device for continuous health monitoring enables us to monitor a patient in their home and recognize when a patient may have an exacerbation of illness even before they manifest symptoms. This may reduce hospitalizations, emergency department visits and shorten hospital stays, creating cost efficiencies for health systems."